Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

  • Awaiting development
  • GID-TA11438
  • Expected publication date: TBC

NIHRIO BN: 29556-Cabozantinib-Atezolizumab-for-Castration-Resistant-Prostate-Cancer-V1.0-SEP2023-NON-CONF.pdf (nihr.ac.uk)